Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.49
+1.6%
$5.19
$3.42
$6.91
$306.96M1.751.88 million shs1.34 million shs
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.68
+3.1%
$1.52
$0.60
$4.18
$76.60M0.76473,890 shs645,738 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$2.09
+4.8%
$1.74
$1.32
$2.71
$306.16M1.87151,451 shs231,230 shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$9.14
+0.6%
$7.91
$6.57
$105.00
$298.24M1.05154,586 shs97,817 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+1.89%-7.06%+10.88%+20.27%-1.28%
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
0.00%-19.70%+13.99%+24.43%-18.50%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-1.00%+2.05%+21.34%+22.09%-3.40%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+0.11%-0.55%+18.05%+5.94%+908,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.49
+1.6%
$5.19
$3.42
$6.91
$306.96M1.751.88 million shs1.34 million shs
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.68
+3.1%
$1.52
$0.60
$4.18
$76.60M0.76473,890 shs645,738 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$2.09
+4.8%
$1.74
$1.32
$2.71
$306.16M1.87151,451 shs231,230 shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$9.14
+0.6%
$7.91
$6.57
$105.00
$298.24M1.05154,586 shs97,817 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+1.89%-7.06%+10.88%+20.27%-1.28%
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
0.00%-19.70%+13.99%+24.43%-18.50%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-1.00%+2.05%+21.34%+22.09%-3.40%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
+0.11%-0.55%+18.05%+5.94%+908,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
2.80
Moderate BuyN/AN/A
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
2.67
Moderate Buy$8.00376.19% Upside
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.00
Hold$7.00235.73% Upside
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2.60
Moderate Buy$19.00107.88% Upside

Current Analyst Ratings Breakdown

Latest HOWL, ACB, JBIO, and IMMP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2025
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$28.00
10/9/2025
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$28.00
10/8/2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E-)
10/6/2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
9/27/2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E-)
(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.25$0.63 per share8.67$7.78 per share0.71
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.88M40.87N/AN/A$1.65 per share1.02
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$6.69M45.87N/AN/A$0.63 per share3.31
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/A$92.88 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M-$0.19N/A12.47N/A-5.66%-1.49%-1.06%11/5/2025 (Estimated)
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$70.51M-$1.64N/AN/AN/AN/A-111.87%-62.68%11/6/2025 (Estimated)
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$39.78MN/A0.00N/AN/AN/AN/AN/AN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$69.63M-$30.33N/AN/AN/A-51.96%-47.65%N/A

Latest HOWL, ACB, JBIO, and IMMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$0.39N/AN/AN/AN/AN/A
11/5/2025Q2 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.03N/AN/AN/A$86.45 millionN/A
8/14/2025Q2 2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$0.50-$0.40+$0.10-$0.40$1.50 millionN/A
8/13/2025Q2 2025
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$0.43-$0.86-$0.43-$0.86N/AN/A
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18-$0.19-$0.37-$0.20$96.83 million$71.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.06
2.97
1.51
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
0.60
5.30
5.30
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
11.69
N/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
10.31
10.31

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
64.84%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
23.60%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
24.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.22 million56.22 millionOptionable
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
4045.73 million34.94 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021147.19 million142.67 millionOptionable
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2032.63 million24.50 millionN/A

Recent News About These Companies

Wedbush Equities Analysts Lower Earnings Estimates for JBIO
Q3 Earnings Forecast for Jade Biosciences Issued By Wedbush
Jade Biosciences Announces $135 Million Private Placement
Jade Biosciences Reports Q2 2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.48 +0.09 (+1.57%)
As of 02:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Werewolf Therapeutics stock logo

Werewolf Therapeutics NASDAQ:HOWL

$1.68 +0.05 (+3.07%)
As of 02:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$2.08 +0.10 (+4.77%)
As of 02:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Jade Biosciences stock logo

Jade Biosciences NASDAQ:JBIO

$9.14 +0.05 (+0.55%)
As of 02:23 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.